International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Royal Marsden NHS Foundation Trust
Cancer Research UK
Information provided by (Responsible Party):
Royal Marsden NHS Foundation Trust Identifier:
First received: January 13, 2014
Last updated: January 30, 2014
Last verified: January 2014

Anal cancer is a relatively uncommon disease and there is currently no standard chemotherapy treatment for patients with inoperable locally recurrent or metastatic disease. The aim of this phase II study is compare two well known and largely used chemotherapy regimens - Cisplatin plus 5-fluorouracil vs Carboplatin plus Paclitaxel. The result of this study will set a standard of care for this disease and provide useful information for future Phase III trials.

Condition Intervention Phase
Squamous Cell Carcinoma of the Anus
Drug: Cisplatin
Drug: 5-Fluorouracil (5-FU)
Drug: Carboplatin
Drug: Paclitaxel
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease

Resource links provided by NLM:

Further study details as provided by Royal Marsden NHS Foundation Trust:

Primary Outcome Measures:
  • Best overall response rate by 24 weeks post treatment [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    Best overall response rate is defined as the percentage of patients achieving confirmed partial or complete responses as per RECIST v1.1 by 24 weeks post treatment start in the intention to treat population. Sensitivity analyse will also be performed.

Secondary Outcome Measures:
  • Feasibility of conducting a multicentre, international study on squamous cell carcinoma of the anus and recruiting within a reasonable time frame. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    The study will be conducted in approximately 50 international centres. This secondary endpoint will be measured by (i) the proportion of centres that successfully recruit at least one patient and (ii) overall recruitment rate. We anticipate and would be able to confirm feasibility if 80% of the centres fully engaged with the study. The aim would be to recruit 80 patients in 36 months (10 by month 6, 20 by month 12, 50 by month 24 and 80 by month 36).

  • Toxicity [ Time Frame: Toxicity will be analysed once all patients have been followed up for at least 4 weeks post treatment. ] [ Designated as safety issue: Yes ]
    Toxicity will be graded according to the NCI CTCAE Version 4.0

  • Progression-free survival [ Time Frame: PFS will be analysed once all patients have been followed up for at least 12 months post treatment. ] [ Designated as safety issue: No ]
    This is calculated from the date of randomisation to the date of confirmed clinical/radiological progression or death from any cause. Patients who are lost to follow-up, withdraw from follow-up or alive and progression free will be censored at the date of last follow-up.

  • Overall survival [ Time Frame: Overall survival will be analysed once all patients have been followed up for at least 12 months post treatment. ] [ Designated as safety issue: No ]
    This is calculated from the date of randomisation to the date of death from any cause. Patients, in whom no death is recorded, will be censored at the date they were last seen alive.

  • Disease control rate [ Time Frame: 12 and 24 weeks post treatment start ] [ Designated as safety issue: No ]
    Disease control rate is defined as complete response, partial response or stable disease, and will be assessed in accordance with the RECIST criteria v1.1.

  • Best overall response rate of non-irradiated lesions [ Time Frame: 24 weeks post treatment start ] [ Designated as safety issue: No ]
    Best overall response of non-irradiated lesions is defined as the percentage of patients achieving confirmed partial response or complete response as per RECIST v1.1 of non-irradiated sites of disease.

  • Anti-tumour activity and magnitude of tumour response [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    Anti-tumour activity and magnitude of response will be captured by waterfall plot analyses and indicate the percentage change in tumour size from baseline to the time of best response.

  • Quality of Life [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    Quality of Life will be evaluated using the EORTC QLQ C30 and EQ-5D-5L questionnaires. The functional and symptomatic scales and global health status from the QLQ C30 and EQ-5D-5L questionnaire will be calculated as per EORTC and EuroQol guidelines, respectively.

  • Identification of potential tumour biomarker [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    Archived tumour tissue (if available) and blood sample will be taken at baseline with a repeat blood sample taken upon progression. Patient can enrol in an optional biomarker study where an additional tumour biopsy would be requested when they progress. The aim of this exploratory analysis is to evaluate the expression of tumour biomarkers in the study population and investigate the association of these with treatment outcome.

Estimated Enrollment: 80
Study Start Date: December 2013
Estimated Study Completion Date: February 2018
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm A
Cisplatin and 5-Fluorouracil
Drug: Cisplatin
Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.
Other Names:
  • Systematic (IUPAC) name: (SP-4-2)-diamminedichloridoplatinum
  • CAS number 15663-27-1 Y
  • ATC code L01XA01
Drug: 5-Fluorouracil (5-FU)
5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.
Other Names:
  • Systematic (IUPAC) name: 5-fluoro-1H,3H-pyrimidine-2,4-dione
  • CAS number 51-21-8 Y
  • ATC code L01BC02
Experimental: Arm B
Carboplatin plus Paclitaxel
Drug: Carboplatin
Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.
Other Names:
  • Systematic (IUPAC) name: cis-diammine(cyclobutane-1,1-dicarboxylate-O,O')platinum(II)
  • CAS number 41575-94-4 Y
  • ATC code L01XA02
Drug: Paclitaxel
Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
Other Names:
  • (2α,4α,5β,7β,10β,13α)-4,10-bis(acetyloxy)-13-{[(2R,3S)- 3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy}- 1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
  • CAS number 33069-62-4 Y
  • ATC code L01CD01

Detailed Description:

Study design: This is an international, multicentre, open label, randomised phase II trial. Patients will be randomised to receive either cisplatin plus 5-FU or carboplatin plus weekly paclitaxel. Region (Europe, North America, South America & Australia), (Eastern Cooperative Oncology Group- ECOG) ECOG performance status (PS) (0-1 vs. 2), HIV status (positive vs. negative) and extent of disease (locally recurrent vs. metastatic) will be used as stratification factors. Overall response rate is the primary endpoint.

Indication: First line treatment of patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anus.

Length of study: Recruitment should be completed within 3 years. The estimated recruitment rate is between 4-6 patients per month once it is established at multiple centres.

Primary Objective: To evaluate best overall response rate by 24 weeks post treatment in the cisplatin plus 5-fluorouracil arm versus the carboplatin plus weekly paclitaxel arm

Secondary Objectives: To evaluate: - Progression-free survival - Overall survival - Disease control rate (stable disease or better) at 12 and 24 weeks - Best overall response of metastatic lesions - Toxicity (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Version 4) - Quality of Life (using EORTC QLQ-C30 version 3 and EQ-5D-5L questionnaires).

To assess: The feasibility of conducting a multicentre international study on squamous cell carcinoma of the anus and recruit within a reasonable time frame.

Exploratory Objective: Explorative biomarker analysis including the collection of archived tumour tissue and blood sample at baseline and upon progression.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Histologically or cytologically verified, uni-dimensionally measurable, inoperable, locally recurrent or metastatic squamous cell carcinoma of the anus.
  2. Age ≥18 years.
  3. ECOG Performance status ≤2.
  4. Measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1.
  5. Previous definitive chemoradiotherapy is permitted for early stage squamous cell carcinoma of the anus.
  6. HIV+ patients will be considered eligible with a CD4 count of ≥200.
  7. Adequate cardiac and respiratory function; absolute neutrophil count (ANC) ≥1.5x10^9/l; white blood cell (WBC) count ≥3x10^9/l; platelets >100x10^9/l; haemoglobin (Hb) ≥9g/dl; creatinine clearance >50ml/minute; serum bilirubin ≤1.5x upper limit of normal (ULN); alanine transaminase (ALT)/aspartate transaminase (AST) ≤2.5x ULN; alkaline phosphatase (ALP) ≤3x ULN.
  8. Fertile men and women must agree to take adequate contraceptive precautions during, and for at least six months after therapy.
  9. Life expectancy of at least 3 months.

Exclusion Criteria

  1. Tumours of adenocarcinoma, melanoma, small cell and basal cell histology are excluded.
  2. Previous chemotherapy, radiotherapy or other investigational drug for surgically unresectable locally recurrent or advanced squamous cell carcinoma of the anus
  3. Current or recent (within 30 days of first study dosing) treatment with another investigational drug or participation in another investigational study.
  4. Documented or symptomatic brain metastases and/or central nervous system metastases or leptomeningeal disease.
  5. Surgery or palliative radiotherapy within 28 days of randomisation.
  6. Clinically significant (i.e. active) cardiac disease (e.g. symptomatic coronary artery disease, uncontrolled cardiac arrhythmia, or myocardial infarction within the last 6 months). Any history of clinically significant cardiac failure.
  7. History of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan.
  8. Lack of physical integrity of the gastro-intestinal tract, malabsorption syndrome (naso-gastric or jejunostomy feeding tube is permitted).
  9. Acute hepatitis C and/or chronic active hepatitis B infection.
  10. Serious active infection requiring i.v. antibiotics at enrolment.
  11. Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
  12. Other clinically significant disease or co-morbidity that may adversely affect the safe delivery of treatment within this trial.
  13. Known hypersensitivity to any of the study drugs or excipients.
  14. Known peripheral neuropathy ≥ grade 1 (absence of deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible).
  15. Pre-existing hearing impairment.
  16. Patients planning for a live vaccine.
  17. Pregnant or lactating females.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02051868

Contact: Sheela Rao, MD, FRCP +44 (0) 0208 642 6011 ext 1380
Contact: Francesco Sclafani, MD +44 (0)) 0208 642 6011 ext 1293

United Kingdom
Royal Marsden NHS Foundation Trust, London & Sutton Recruiting
Sutton, United Kingdom, SM2 5PT
Contact: Annette Bryant, BSc (Hons)    +44 (0) 0208 661 3637 ext 3637   
Principal Investigator: Sheela Rao, MD.FRCP         
Sponsors and Collaborators
Royal Marsden NHS Foundation Trust
Cancer Research UK
Principal Investigator: Sheela Rao, MD, FRCP Royal Marsden NHS Foundation Trust
  More Information

No publications provided

Responsible Party: Royal Marsden NHS Foundation Trust Identifier: NCT02051868     History of Changes
Other Study ID Numbers: CCR 3847 InterAACT, 2013-001949-13
Study First Received: January 13, 2014
Last Updated: January 30, 2014
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
United Kingdom: National Health Service
United Kingdom: National Institute for Health Research
United Kingdom: Research Ethics Committee

Keywords provided by Royal Marsden NHS Foundation Trust:
Squamous cell carcinoma of the anus
Anal cancer
Cancer of the anus
locally recurrent

Additional relevant MeSH terms:
Anus Neoplasms
Carcinoma, Squamous Cell
Anus Diseases
Colorectal Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Rectal Diseases
Rectal Neoplasms
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators processed this record on October 08, 2015